How much vaginal estrogen do you use, and how often?
Most low-dose vaginal estrogen follows a loading-then-maintenance pattern: a small daily dose for about two weeks, then a maintenance dose a few times a week. The exact amount depends on the product, because the creams, the tablet or insert, and the ring are each dosed differently.
Low-dose vaginal estrogen is a local treatment for genitourinary syndrome of menopause (GSM), sometimes called vaginal atrophy. It is applied in the vagina and very little reaches the bloodstream, which is why it does not need added progestogen or routine testing of the uterine lining. That is a separate question from systemic hormone therapy. Across the standard low-dose products, blood estradiol stays within the normal postmenopausal range.
What “low dose” means
“Low dose” describes the small amount of estrogen these products deliver locally. Estradiol 0.01% cream is a low-dose product: each gram contains 0.1 mg of estradiol, and it is one of the FDA-approved low-dose vaginal estrogen creams for GSM. The 0.01% on the label is the concentration, not a sign that it is weaker than it should be. All of these products are designed to treat the tissue directly while keeping the dose that reaches the rest of the body very low.
The standard regimens by form
The FDA-approved low-dose products are dosed like this:
- Estradiol 0.01% cream (0.1 mg of estradiol per gram): 0.5 to 1 gram daily for 2 weeks, then 0.5 to 1 gram 1 to 3 times per week.
- Conjugated estrogen cream (0.625 mg per gram): 0.5 to 1 gram daily for 2 weeks, then 0.5 gram 1 to 3 times per week. A commonly used version of this is 0.5 gram daily for 2 weeks, then 0.5 gram twice weekly.
- Estradiol tablet or insert (4 or 10 micrograms): one 10-microgram dose daily for 2 weeks, then twice weekly.
- Estradiol ring: a 2 mg ring that releases about 7.5 micrograms per day and is replaced about every 90 days. It gives a steady low dose with nothing to apply daily or weekly, which suits people who prefer not to use a vaginal product every few days.
The creams and the tablet or insert share the same rhythm: a daily dose for the first two weeks, then a smaller number of doses per week to maintain the effect. The ring works differently, releasing its dose continuously.
Research comparing these forms against each other has not found a meaningful difference in how well they relieve symptoms, so the choice among them comes down to preference, ease of use, and cost. Relief is gradual either way. Improvement may start within a few weeks, but the full benefit usually takes 8 to 12 weeks.
More is not better
The maintenance dose is smaller than the starting dose, and higher is not better. In one comparison, a higher-than-standard cream dose, 1.25 mg of conjugated estrogen in 2 grams of cream daily, which is more than typical practice, left more women with blood estradiol above postmenopausal levels than a low-dose tablet did. That is the reason the standard low doses above are used rather than larger amounts. Once symptoms are controlled, the goal is the smallest effective dose, not the largest.
Follow your product’s instructions
Strengths and measuring are not the same from one product to the next. Estradiol cream is a 0.01% cream measured in grams, conjugated estrogen cream is a 0.625 mg per gram cream measured in grams, the tablet or insert is measured in micrograms, and the ring delivers a fixed daily amount on its own. Because the amounts and the applicators are not interchangeable, follow the specific instructions for the product you were prescribed rather than a general rule of thumb. If you are unsure how much to use or how often, ask the clinician who prescribed it.
References
- Kaufman MR, Ackerman AL, Amin KA, et al. Genitourinary Syndrome of Menopause: AUA/SUFU/AUGS Guideline. American Urological Association. 2025.
- Anger J, Lee U, Ackerman AL, et al. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. American Urological Association / Canadian Urological Association / SUFU. 2019.
- Rahn DD, Carberry C, Sanses TV, et al. Vaginal Estrogen for Genitourinary Syndrome of Menopause: A Systematic Review. Obstetrics & Gynecology. 2014. doi:10.1097/AOG.0000000000000526
- Faubion SS, Sood R, Kapoor E. Genitourinary Syndrome of Menopause: Management Strategies for the Clinician. Mayo Clinic Proceedings. 2017. doi:10.1016/j.mayocp.2017.08.019
- Ringel NE, Iglesia C. Common Benign Chronic Vulvar Disorders. American Family Physician. 2020.
← Learn more about Vaginal Estrogen